Midcap Stocks Research: Subscribe for 1 Year... Get Access for 3 Years
Here is the latest financial fact sheet of SYNCOM FORMULATIONS. For more details, see the SYNCOM FORMULATIONS quarterly results and SYNCOM FORMULATIONS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -1.2 |
No. of shares | m | 940.00 |
1 Week | % | -8.2 |
1 Month | % | -7.2 |
1 Year | % | 107.6 |
52 week H/L | Rs | 18.7/6.1 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
SYNCOM FORMULATIONS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 2 | 1 | 4 | 19 | 13 | |
Low | Rs | 1 | NA | 1 | 3 | 5 | |
Sales per share (Unadj.) | Rs | 2.4 | 2.6 | 3.1 | 2.5 | 2.4 | |
Earnings per share (Unadj.) | Rs | 0.1 | 0.2 | 0.4 | 0.2 | 0.2 | |
Diluted earnings per share | Rs | 0.1 | 0.2 | 0.3 | 0.2 | 0.2 | |
Cash flow per share (Unadj.) | Rs | 0.2 | 0.2 | 0.4 | 0.3 | 0.3 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 1.7 | 1.9 | 2.3 | 2.5 | 2.7 | |
Adj. book value per share | Rs | 1.4 | 1.5 | 1.9 | 2.3 | 2.7 | |
Shares outstanding (eoy) | m | 780.65 | 780.65 | 789.95 | 862.45 | 940.00 | |
Price / Sales ratio | x | 0.5 | 0.3 | 0.7 | 4.4 | 3.7 | |
Avg P/E ratio | x | 7.9 | 4.4 | 6.3 | 49.1 | 41.1 | |
P/CF ratio (eoy) | x | 5.8 | 3.4 | 5.5 | 40.9 | 33.5 | |
Price / Book Value ratio | x | 0.7 | 0.4 | 1.0 | 4.5 | 3.2 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 874 | 625 | 1,833 | 9,716 | 8,249 | |
Total wages/salary | Rs m | 152 | 158 | 182 | 207 | 244 |
SYNCOM FORMULATIONS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 1,868 | 2,055 | 2,448 | 2,197 | 2,243 | |
Other income | Rs m | 51 | 52 | 71 | 120 | 146 | |
Total revenues | Rs m | 1,919 | 2,107 | 2,519 | 2,317 | 2,389 | |
Gross profit | Rs m | 118 | 167 | 381 | 201 | 199 | |
Depreciation | Rs m | 40 | 41 | 40 | 39 | 45 | |
Interest | Rs m | 2 | 6 | 5 | 19 | 34 | |
Profit before tax | Rs m | 127 | 173 | 407 | 262 | 266 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 16 | 30 | 115 | 64 | 65 | |
Profit after tax | Rs m | 111 | 143 | 292 | 198 | 201 | |
Gross profit margin | % | 6.3 | 8.1 | 15.6 | 9.1 | 8.9 | |
Effective tax rate | % | 12.5 | 17.6 | 28.3 | 24.4 | 24.5 | |
Net profit margin | % | 5.9 | 6.9 | 11.9 | 9.0 | 8.9 |
SYNCOM FORMULATIONS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 813 | 894 | 1,898 | 1,398 | 1,817 | |
Current liabilities | Rs m | 358 | 312 | 967 | 783 | 1,132 | |
Net working cap to sales | % | 24.4 | 28.3 | 38.0 | 28.0 | 30.6 | |
Current ratio | x | 2.3 | 2.9 | 2.0 | 1.8 | 1.6 | |
Inventory Days | Days | 91 | 86 | 30 | 183 | 231 | |
Debtors Days | Days | 80,767,198 | 76,978,436 | 1,116 | 1,122 | 1,229 | |
Net fixed assets | Rs m | 947 | 945 | 1,018 | 1,684 | 1,961 | |
Share capital | Rs m | 781 | 781 | 790 | 862 | 940 | |
"Free" reserves | Rs m | 546 | 676 | 988 | 1,309 | 1,620 | |
Net worth | Rs m | 1,326 | 1,457 | 1,778 | 2,172 | 2,560 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 1,760 | 1,839 | 2,917 | 3,082 | 3,778 | |
Interest coverage | x | 52.5 | 29.2 | 86.3 | 14.6 | 8.8 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.1 | 1.1 | 0.8 | 0.7 | 0.6 | |
Return on assets | % | 6.4 | 8.1 | 10.2 | 7.0 | 6.2 | |
Return on equity | % | 8.4 | 9.8 | 16.4 | 9.1 | 7.8 | |
Return on capital | % | 9.7 | 12.3 | 23.2 | 12.9 | 11.7 | |
Exports to sales | % | 60.4 | 59.8 | 69.7 | 65.9 | 63.3 | |
Imports to sales | % | 0.1 | 0.6 | 0.2 | 1.8 | 7.7 | |
Exports (fob) | Rs m | 1,127 | 1,229 | 1,707 | 1,447 | 1,419 | |
Imports (cif) | Rs m | 2 | 12 | 4 | 39 | 172 | |
Fx inflow | Rs m | 1,127 | 1,229 | 1,707 | 1,447 | 1,419 | |
Fx outflow | Rs m | 3 | 14 | 4 | 56 | 204 | |
Net fx | Rs m | 1,124 | 1,215 | 1,704 | 1,391 | 1,215 |
SYNCOM FORMULATIONS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 43 | 59 | -21 | 163 | 105 | |
From Investments | Rs m | 24 | 15 | -754 | -271 | -450 | |
From Financial Activity | Rs m | -2 | -65 | 720 | 83 | 350 | |
Net Cashflow | Rs m | 66 | 9 | -55 | -25 | 6 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Kedarmal Bankda | COMP SEC: Prachi Jain | YEAR OF INC: 1988 | BSE CODE: 524470 | FV (Rs): 1 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare SYNCOM FORMULATIONS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Indian share markets Slipped further as the session progressed and ended the day weak.